Siqueiros v. General Motors LLC ( 2020 )

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 MONTEVILLE SLOAN, et al., Case No. 16-cv-07244-EMC 8 Plaintiffs, ORDER GRANTING DEFENDANT’S 9 v. MOTION FOR RECONSIDERATION AND DISMISSING THE CLAIMS OF 10 GENERAL MOTORS LLC, ADDITIONAL PLAINTIFFS 11 Defendant. Docket No. 221 12 13 14 I. INTRODUCTION 15 Defendant General Motors (“GM” or “Defendant”) moves the Court for reconsideration of 16 its order from February 7, 2018, specifically on the question “whether the Court has personal 17 jurisdiction over the five out-of-state plaintiffs added in the second amended complaint.” Motion 18 for Reconsideration (“Mot.”) at 1, Docket No. 221. Those five out-of-state Plaintiffs are Illinois 19 Plaintiffs Edwin and Katelyn Doepel, New York Plaintiff Dennis Vita, Oregon Plaintiff William 20 Martell, and Washington Plaintiff Kelly Harris. Id. at 2. The motion stems from the Court’s 21 December 5, 2019 order, dismissing the claims of the Ohio Plaintiff for lack of personal 22 jurisdiction. At the hearing regarding dismissal of those claims, the Court contemplated that, were 23 it to conclude that it lacked personal jurisdiction as to the claims of the Ohio Plaintiff, it would 24 likely need to reconsider personal jurisdiction as to the claims of the five plaintiffs added in the 25 Second Amended Complaint. See Transcript of Proceedings from September 12, 2019 26 (“Transcript”) at 17:1–16, Docket No. 197. GM now seeks reconsideration of that issue, in light 27 of the Court’s order from December 5, 2019. 1 II. BACKGROUND 2 Plaintiffs filed a Second Amended Complaint (“SAC”) in this case on August 31, 2017. 3 See Docket No. 67. That SAC added five new Plaintiffs: Illinois Plaintiffs Edwin and Katelyn 4 Doepel, New York Plaintiff Dennis Vita, Oregon Plaintiff William Martell, and Washington 5 Plaintiff Kelly Harris. Id. GM filed a Motion to Dismiss the Second Amended Complaint, 6 arguing—among other things—that the Court lacked personal jurisdiction over the claims of non- 7 California Plaintiffs, including the newly added Plaintiffs from Illinois, New York, Oregon, and 8 Washington. See Docket No. 70. On February 7, 2018, after extensive supplemental briefing, the 9 Court issued an order granting in part and denying in part that motion. See Docket No. 99. In that 10 order, the Court concluded that the existence of federal question jurisdiction precluded the 11 application of Bristol-Myers Squibb Co. v. Superior Court of California, 137 S. Ct. 1773 (2017); 12 the Court therefore found it proper to exercise pendent personal jurisdiction over the claims of the 13 newly added non-California Plaintiffs. Id. 14 In July 2019, Plaintiffs filed a Fifth Amended Complaint, which added a Plaintiff from 15 Ohio. See Docket No. 157. GM moved to dismiss the claims of the Ohio Plaintiff for lack of 16 personal jurisdiction. See Docket No. 158. On December 5, 2019, the Court dismissed the claims 17 of the Ohio Plaintiff on the grounds that it lacked personal jurisdiction over those claims. See 18 Docket No. 195 (“5AC Order”). In so doing, the Court noted first that “there is no federal 19 question furnishing federal question jurisdiction as it relates to Plaintiff Szep’s claims.” 5AC 20 Order at 11. Federal question jurisdiction had not been pled by Plaintiffs, and the Ohio Plaintiff 21 had no viable Magnuson Moss Warranty Act claim (which might otherwise furnish a basis for 22 federal question jurisdiction). Id. Next, the Court observed that “nearly every court considering 23 the issue has concluded pendent party jurisdiction cannot be exercised by a federal court sitting in 24 diversity.” Id. at 14. Because pendent party jurisdiction was the sole basis for personal 25 jurisdiction advanced by Plaintiffs, the Court concluded that because it would be inappropriate to 26 exercise pendent party jurisdiction, the Court lacked personal jurisdiction over the claims of the 27 Ohio Plaintiff. See id. at 14–16. 1 As noted above, at the hearing regarding GM’s Motion to Dismiss the claims of the Ohio 2 Plaintiff, the Court contemplated the possibility that, should it conclude it lacked personal 3 jurisdiction as to the claims of the Ohio Plaintiff, GM would likely request that the Court 4 reconsider the existence of personal jurisdiction as to the claims of the five plaintiffs added in the 5 Second Amended Complaint. See Transcript at 17:1–16. On December 23, 2019, GM filed such 6 a motion. See Docket No. 200. On December 24, 2020, the Court granted GM’s Motion for 7 Leave to File a Motion for Reconsideration. See Docket No. 208. Also pending before the Court 8 are Plaintiff’s Motion for Class Certification, see Docket No. 175, Defendant’s Motion for Partial 9 Summary Judgment, see Docket No. 184, and Defendant’s Motion to Exclude Certain Expert 10 Testimony, see Docket No. 201. 11 III. DISCUSSION 12 Plaintiffs effectively concede that—in light of the Court’s order dismissing the claims of 13 the Ohio Plaintiff—the claims of Illinois Plaintiffs Edwin and Katelyn Doepel, Oregon Plaintiff 14 William Martell, and Washington Plaintiff Kelly Harris should be dismissed for lack of personal 15 jurisdiction.1 See Plaintiffs’ Opposition to General Motors’ Motion for Reconsideration (“Opp.”) 16 at 1, 1 n.1, Docket No. 232. However, Plaintiffs contend that New York Plaintiff Dennis Vita has 17 a valid claim under the Magnuson-Moss Warranty Act, which raises a federal question that 18 “permits this Court to exercise pendent personal jurisdiction over Plaintiff Vita’s claims 19 notwithstanding Bristol-Myers.” Id. at 1. Thus, Plaintiffs argue that “GM’s Motion should, at 20 minimum, be denied with respect to Plaintiff Vita.” Id. at 3. 21 According to the MMWA statute, for cases filed in federal district courts where the action 22 is a class action, no claim shall be cognizable if “the number of named plaintiffs is less than one 23 24 1 Plaintiffs specifically state: “The other SAC Plaintiffs have also pled MMWA claims but only 25 for the purpose of preserving them for appeal in light of this Court’s previous orders dismissing their express and implied warranty claims. See Docket No. 157 at 63 nn.40–41, 189 n.45. 26 Plaintiffs respectfully submit that, for the reasons discussed in Plaintiffs’ briefing with respect to GM’s motion to dismiss Mr. Szep’s claims, this court nonetheless may exercise personal 27 jurisdiction over these Plaintiffs’ claims, see Docket Nos. 161, 179, but recognize that this Court 1 hundred.” 15 U.S.C. § 2310(d). Plaintiffs here do not meet that requirement.2 2 To be sure, some courts interpreting this provision “have held that the requirement is 3 satisfied when plaintiffs properly invoke jurisdiction under the Class Action Fairness Act 4 (‘CAFA’). These cases hold that where the party invoking federal jurisdiction is able to meet his 5 or her burden of proving jurisdiction under CAFA, the absence of at least one hundred named 6 plaintiffs does not prevent the plaintiff from asserting claims under the Magnuson–Moss Warranty 7 Act.” Keegan v. Am. Honda Motor Co., 838 F. Supp. 2d 929, 954 (C.D. Cal. 2012); see also 8 Morgan v. Apple Inc., No. 17-CV-05277-RS, 2018 WL 2234537, at *8 (N.D. Cal. May 16, 2018) 9 (citing Keegan, 838 F. Supp. 2d at 954) (“While Apple initially argues that plaintiffs’ MMWA 10 claims fail for the separate reason that they lack at least 100 named plaintiffs, the MMWA’s 11 requirements are satisfied as plaintiffs have invoked jurisdiction under the Class Action Fairness 12 Act.”). On the other hand, other courts have rejected that jurisdictional analysis. See MacDougall 13 v. Am. Honda Motor Co., No. SACV1701079AGDFMX, 2017 WL 8236359, at *4 (C.D. Cal. 14 Dec. 4, 2017) (“Plaintiffs’ argument that the Court can exercise jurisdiction over their Magnuson- 15 Moss Act claim through CAFA is nonsensical. CAFA—a basis for federal courts to exercise 16 jurisdiction over state law disputes between diverse parties—doesn’t fill in the gaps for missing 17 substantive requirements of a federal law.”); Floyd v. Am. Honda Motor Co., No. 2:17-CV-08744- 18 SVW-AS, 2018 WL 6118582, at *3 (C.D. Cal. June 13, 2018) (“this Court declines to follow 19 Keegan and similar cases and instead follows MacDougall in requiring Plaintiffs to meet the 20 jurisdictional standards and pleading standards imposed by both CAFA and MMWA”). 21 Irrespective of the divide on the general question of jurisdiction, Plaintiffs contend that his 22 MMWA claim, asserted via CAFA jurisdiction, establishes the existence of federal question 23 jurisdiction,3 and that this permits pendent personal jurisdiction. Opp. at 5. 24 2 Although Plaintiff Vita brings his MMWA count individually and on behalf of a class, Section 25 2310 provides: “No claim shall be cognizable in a suit brought [in federal district court] . . . if the action is brought as a class action, and the number of named plaintiffs is less than one hundred.” 26 15 U.S.C. § 2310(d)(3) (emphasis added). Thus, it appears that whether the claim is cognizable turns on whether the suit is a class action; the suit herein is a class action. 27 1 Plaintiffs’ argument is unpersuasive. Plaintiffs have only pled diversity jurisdiction. This 2 || is consistent with the fact that CAFA constituted an expansion of diversity jurisdiction; it does not, 3 || on its own, purport to establish federal question jurisdiction. Indeed, several courts have 4 || recognized the distinction between diversity jurisdiction under CAFA and federal question 5 jurisdiction furnished by MMWA claims. See, e.g., Chavis v. Fid. Warranty Servs., Inc., 415 F. 6 || Supp. 2d 620, 627 (D.S.C. 2006) (discussing the fact that “the Report and Recommendation 7 acknowledges that where the federal question jurisdictional requirements in the M/M Act (15 8 U.S.C. § 2310(d)(3)(B)) are not satisfied, diversity jurisdiction as set forth in 28 U.S.C. § 1332 9 may still be appropriate to retain federal jurisdiction over Magnusson—Moss claims” (emphasis 10 added)); Haslam v. Lefta, Inc., No. 93 C 4311, 1994 WL 117463, at *2 (N.D. Ill. Mar. 25, 1994) 11 (“For substantially the same reasons set forth in Werzel, this Court finds that diversity jurisdiction 12 || is limited solely by the requirements set forth in § 1332, and not by the federal question 5 13 || jurisdictional requirements in the MMWA § 2310(d)(3)(B).” (emphasis added)). Consequently, 14 even if Plaintiff Vita is able to assert a viable MMWA claim in this case by virtue of CAFA, that 3 15 claim would not furnish federal question jurisdiction. Accordingly, it is not a basis, under current a 16 law, to distinguish Bristol-Myers. IV. CONCLUSION 18 Accordingly, the Court GRANTS Defendants’ Motion for Reconsideration and 19 DISMISSES the claims of Plaintiffs Edwin and Katelyn Doepel, Dennis Vita, William Martell, 20 and Kelly Harris. 21 This order disposes of Docket No. 221. 22 IT IS SO ORDERED. 23 Dated: February 11, 2020 Ey 95 ED M. CHEN United States District Judge 26 97 || Arutunian v. Mercedes-Benz USA, LLC, No. CV186806DMGRAOX, 2018 WL 6617636, at *3 (C.D. Cal. Dec. 17, 2018) (“the Court has federal question jurisdiction over Plaintiffs MMWA 2g || claims”); Luna v. BMW of N. Am., LLC, No. 317CV02067BENKSC, 2018 WL 2328365, at *4 (S.D. Cal. May 22, 2018) (“the Court has federal question jurisdiction over the MMWA claim”’)).